NK Cells + N-803 for Kidney and Bladder Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot have had anti-tumor chemotherapy or investigational agents within 2 weeks prior to enrollment, or immunotherapy within 4 weeks prior. Also, you cannot be on systemic corticosteroid therapy at a dose of 10 mg or more of prednisone (or equivalent) for at least 2 weeks before enrolling.
What data supports the effectiveness of the treatment NK Cells + N-803 for Kidney and Bladder Cancer?
Research shows that cytokine-induced memory-like natural killer (CIML NK) cells, which are part of this treatment, have demonstrated enhanced anticancer functionality and promising clinical activity in early trials. Additionally, similar treatments using cytokine-induced killer (CIK) cells have shown effectiveness in treating renal cell carcinoma, with some patients experiencing complete or partial responses.12345
Is the NK Cells + N-803 treatment safe for humans?
What makes the NK Cells + N-803 treatment unique for kidney and bladder cancer?
This treatment is unique because it uses cytokine-induced memory-like (CIML) natural killer (NK) cells, which are enhanced by a combination of cytokines (IL-12, IL-15, and IL-18) to improve their longevity and anticancer functionality. This approach aims to overcome the limitations of traditional NK cell therapies by boosting their ability to remember and respond more effectively to cancer cells.345910
What is the purpose of this trial?
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma.Names of the study therapies involved in this study are/is:* CIML NK cell therapy (a NK cell therapy)* IL-2 (a type of cytokine)
Research Team
Wenxin Xu, MD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for adults with advanced renal cell carcinoma or urothelial carcinoma. Participants must have measurable disease and be able to provide a sample of their tumor tissue. They should not have had any other cancer treatments like chemotherapy, radiation, or surgery within the last 4 weeks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Leukapheresis and Chemotherapy
Collection of NK cells through leukapheresis and administration of lymphodepleting chemotherapy
Treatment
Administration of CIML NK Cell Therapy and low dose IL-2
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
- N-803
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Kidney Cancer Association
Collaborator
ImmunityBio, Inc.
Industry Sponsor
Richard Adcock
ImmunityBio, Inc.
Chief Executive Officer since 2024
Information not available
Dr. Patrick Soon-Shiong
ImmunityBio, Inc.
Chief Medical Officer since 2021
MD